Literature DB >> 33456707

Carving a niche for immunotherapy in ovarian cancer.

Nitasha Gupta, Erika Lampert, Jung-Min Lee.   

Abstract

Entities:  

Keywords:  PARP inhibitor; combination therapy; immunotherapy; ovarian cancer

Year:  2021        PMID： 33456707      PMCID： PMC7800774          DOI： 10.18632/oncotarget.27864

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  14 in total

1.  Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Authors:  U A Matulonis; R Shapira-Frommer; A D Santin; A S Lisyanskaya; S Pignata; I Vergote; F Raspagliesi; G S Sonke; M Birrer; D M Provencher; J Sehouli; N Colombo; A González-Martín; A Oaknin; P B Ottevanger; V Rudaitis; K Katchar; H Wu; S Keefe; J Ruman; J A Ledermann
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

2.  Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Authors:  Jung-Min Lee; Ashley Cimino-Mathews; Cody J Peer; Alexandra Zimmer; Stanley Lipkowitz; Christina M Annunziata; Liang Cao; Maria I Harrell; Elizabeth M Swisher; Nicole Houston; Dana-Adriana Botesteanu; Janis M Taube; Elizabeth Thompson; Aleksandra Ogurtsova; Haiying Xu; Jeffers Nguyen; Tony W Ho; William D Figg; Elise C Kohn
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

Review 3.  Mechanisms of PARP inhibitor sensitivity and resistance.

Authors:  Alan D D'Andrea
Journal:  DNA Repair (Amst)       Date:  2018-08-23

4.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.

Authors:  Shiping Jiao; Weiya Xia; Hirohito Yamaguchi; Yongkun Wei; Mei-Kuang Chen; Jung-Mao Hsu; Jennifer L Hsu; Wen-Hsuan Yu; Yi Du; Heng-Huan Lee; Chia-Wei Li; Chao-Kai Chou; Seung-Oe Lim; Shih-Shin Chang; Jennifer Litton; Banu Arun; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2017-02-06       Impact factor: 12.531

5.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

6.  Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.

Authors:  Erika J Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R Nair; Yingmiao Liu; Elizabeth M Swisher; James W Hodge; Andrew B Nixon; Erin Nichols; Mohammad H Bagheri; Elliott Levy; Marc R Radke; Stanley Lipkowitz; Christina M Annunziata; Janis M Taube; Seth M Steinberg; Jung-Min Lee
Journal:  Clin Cancer Res       Date:  2020-05-12       Impact factor: 12.531

7.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Authors:  Panagiotis A Konstantinopoulos; Steven Waggoner; Gregory A Vidal; Monica Mita; John W Moroney; Robert Holloway; Linda Van Le; Jasgit C Sachdev; Eloise Chapman-Davis; Gerardo Colon-Otero; Richard T Penson; Ursula A Matulonis; Young Bae Kim; Kathleen N Moore; Elizabeth M Swisher; Anniina Färkkilä; Alan D'Andrea; Erica Stringer-Reasor; Jing Wang; Nathan Buerstatte; Sujata Arora; Julie R Graham; Dmitri Bobilev; Bruce J Dezube; Pamela Munster
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 31.777

Review 8.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Authors:  T A Chan; M Yarchoan; E Jaffee; C Swanton; S A Quezada; A Stenzinger; S Peters
Journal:  Ann Oncol       Date:  2019-01-01       Impact factor: 32.976

9.  Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.

Authors:  Kathleen E Fenerty; Michelle Padget; Benjamin Wolfson; Sofia R Gameiro; Zhen Su; John H Lee; Shahrooz Rabizadeh; Patrick Soon-Shiong; James W Hodge
Journal:  J Immunother Cancer       Date:  2018-11-29       Impact factor: 13.751

10.  Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

Authors:  Doga C Gulhan; Julia Casado; Alan D D'Andrea; Panagiotis A Konstantinopoulos; Anniina Färkkilä; Connor A Jacobson; Huy Nguyen; Bose Kochupurakkal; Zoltan Maliga; Clarence Yapp; Yu-An Chen; Denis Schapiro; Yinghui Zhou; Julie R Graham; Bruce J Dezube; Pamela Munster; Sandro Santagata; Elizabeth Garcia; Scott Rodig; Ana Lako; Dipanjan Chowdhury; Geoffrey I Shapiro; Ursula A Matulonis; Peter J Park; Sampsa Hautaniemi; Peter K Sorger; Elizabeth M Swisher
Journal:  Nat Commun       Date:  2020-03-19       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.